Drug Profile
Apoptin gene therapy
Alternative Names: Ad-VP3Latest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Leadd
- Class Antineoplastics; Gene therapies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Jun 2003 Preclinical trials in Cancer in USA (unspecified route)
- 19 Jul 2000 New profile
- 19 Jul 2000 Preclinical development for Cancer in Netherlands (Unknown route)